NRx Pharmaceuticals NRXP is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for NRXP’s loss per share is pinned at 20 cents. In the absence of a marketed ...

NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2024 Earnings Call Transcript August 15, 2024 Operator: Good afternoon, everyone. And welcome to the NRx Pharmaceuticals Incorporated Second Quarter of ...

RADNOR, Pa., Aug. 14, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals (NRXP)", the "Company"), a clinical-stage biopharmaceutical company, today announced its ...

This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 26, 2025 (NEWMEDIAWIRE) - NRx ...

For the year ended December 31, 2024, NRx Pharmaceuticals reduced its loss from operations by approximately $9.3 million, or 33.5%, to $18.5 million from $27.8 million for the year ended December ...

Review the current NRX Pharmaceuticals Inc Ordinary Shares (NRXP:XNAS) dividend yield and history to decide if NRXP is the best investment for you.

Shares of NRx Pharmaceuticals stock opened at $2.01 on Monday. The stock’s fifty day moving average price is $2.70 and its 200-day moving average price is $2.04. The firm has a market cap of $34 ...

About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system ...

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for treating central nervous system disorders.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ETCompany ParticipantsMatthew Duffy - Chief Business ...

Operator: Good afternoon, everyone. And welcome to the NRx Pharmaceuticals Incorporated Second Quarter of 2024 Results Conference Call. Currently, all participants are in a listen-only mode.